The NEOSPHERE trial demonstrated significant improvement of pCR rates using dual targeting of the HER2 receptor with trastuzumab and pertuzumab. Schuld wenn use this dual targeting strategy in clinical routine or should we wait for the results so the adjuvant APHINITY trial because of the disappointing results of the ALTTO trial with dual trastuzumab and lapatinib ?
In my opinion we shoukd recommend dual targeting of tthe HER2 receptor with herceptin and pertuzumab in neadjuvant setting. Best regards
I don`t believe that dual blockade with trastuzumab and pertuzumab can be compared to dual blockade with trastuzumab and lapatinib. Of course I share your disappointment about the results of ALTTO compared to NeoALTTO. But we must not forget what we learned about both kinds of dual blockade in the metastatic setting and that trastuzumab and pertuzumab are approved for neoadjuvant therapy whereas for the combination trastuzumab and lapatinib not even an application for approval has ever been filed. And if we need even more encouragement, we just have to take a look at individual patients in GeparOcto and ADAPT. We have started dual blockade in neoadjuvant patients since the week of the approval.
- Badges
- Science topic
- Similar topics
- Chemistry
- Pharmacology